Kings Path Partners LLC Lowers Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Kings Path Partners LLC trimmed its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 49.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,920 shares of the medical instruments supplier's stock after selling 8,813 shares during the period. Kings Path Partners LLC's holdings in LeMaitre Vascular were worth $748,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. New York State Teachers Retirement System grew its stake in LeMaitre Vascular by 1.2% in the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock valued at $755,000 after buying an additional 100 shares during the last quarter. Flputnam Investment Management Co. grew its stake in LeMaitre Vascular by 3.6% in the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock valued at $269,000 after buying an additional 102 shares during the last quarter. Norden Group LLC boosted its holdings in LeMaitre Vascular by 4.5% in the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 103 shares during the period. Blue Barn Wealth LLC boosted its holdings in LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock valued at $229,000 after purchasing an additional 104 shares during the period. Finally, Shaker Investments LLC OH raised its stake in LeMaitre Vascular by 0.8% during the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock worth $1,285,000 after acquiring an additional 112 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 1.9%

Shares of NASDAQ:LMAT traded up $1.54 on Tuesday, hitting $81.94. The company had a trading volume of 34,500 shares, compared to its average volume of 168,132. The firm's 50-day simple moving average is $83.78 and its two-hundred day simple moving average is $91.50. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of 44.78, a P/E/G ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. During the same period last year, the firm posted $0.44 EPS. The company's revenue for the quarter was up 12.0% on a year-over-year basis. Equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were paid a dividend of $0.20 per share. The ex-dividend date was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price on the stock. Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital upped their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $97.83.

Insider Buying and Selling

In related news, CEO George W. Lemaitre sold 4,399 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total transaction of $374,354.90. Following the completion of the transaction, the chief executive officer now owns 1,827,003 shares in the company, valued at $155,477,955.30. The trade was a 0.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 102,009 shares of company stock valued at $8,721,836. Company insiders own 9.50% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.